As the agreement’s first work assignment, Metanomics Health has commissioned Cenix to undertake a target validation project for an undisclosed disease indication. Under the jointly developed work plan, Cenix will leverage its longstanding industry-leading expertise in high content screening, utilizing the Definiens XD image analysis platform, for comprehensive functional characterization of target genes designated by Metanomics Health.
“We foresee very strong synergies between our own capabilities and the exciting approach taken by Metanomics Health towards biomarker discovery and validation,” said Dr. Christophe Echeverri, CEO/CSO of Cenix. “We appreciate and value the trust of our colleagues at Metanomics Health and look forward to advancing their programs”.
Financial terms were not disclosed.